Characterisation of the cytotoxic alloresponse of cord blood

Bone Marrow Transplantation

Volumn 22, Issue SUPPL. 1, 1998, Pages

  Barbey, C ^a   Irion, O ^a   Helg, C ^a   Chapuis, B ^a   Grand, C ^a   Chizzolini, C ^a   Jeannet, M ^a   Roosnek, E ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Alloresponse; Cord blood; CTL

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; HLA ANTIGEN; INTERLEUKIN 2;

ALLOIMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; UMBILICAL CORD BLOOD;

ADULT; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FETAL BLOOD; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; INFANT, NEWBORN; INTERLEUKIN-2; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031927019     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Devergie A, Apperley JF, Labopin M et al. European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Bone Marrow Transplant 1997; 20: 11-19.
2. Wagner JE, Rosenthal J, Sweetman R et al. Successful transplantation of HLA-matehed and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996; 88: 795-802.
3. Fernandez MN, Regidor C, Diez JL et al. HLA haploidentical cord blood cell transplant in a 15-year-old, 50 kg weight patient: successful treatment for chronic myeloid leukemia after myeloid blastic transformation. Bone Marrow Transplant 1996; 17: 1175-1178.
4. Vilmer, E, Sterkers G, Rahimy C et al. HLA-mismatched cord-blood transplantation in a patient with advanced leukemia (see comments). Transplantation 1992; 53: 1155-1157.
5. Gluckman E, Rocha V, Boyer-Chammard A et al. Outcome of cord blood transplantation from related and unrelated donors. New Engl J Med 1997; 337: 373-381.
6. Harris DT, Lo Cascio J, Besencon FJ. Analysis of the alloreactive capacity of human umbilical cord blood: implications for graft-versus-host disease. Bone Marrow Transplant 1994; 14: 545-553.
7. Harris DT, Schumacher MJ, Lo Cascio J et al. Immunoreactivity of umbilical cord blood and post-partum maternal peripheral blood with regard to HLA-haploidentical transplantation. Bone Marrow Transplant 1994; 14: 63-68.
8. Keever CA, Abu-Hajir M, Graf W et al. Characterization of the alloreactivity and anti-leukemia reactivity of cord blood mononuclear cells. Bone Marrow Transplant 1995; 15: 407-419.
9. Risdon G, Gaddy J, Horie M, Broxmeyer HE. Alloantigen priming induces a state of unresponsiveness in human umbilical cord blood T cells. Proc Natl Acad Sci USA 1995; 92: 2413-2417.
10. + Tel and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. J Immunol 1996; 157: 4811-4821.
11. Truitt RL, Atasoylu AA. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 1991; 8: 51.
12. Fowler DH, Kurasawa K, Smith R et al. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graaft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 1994; 84: 3540-3549.
13. Fowler DH, Kurasawa K, Husebekk A et al. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment. J Immunol 1994; 152: 1004-1013.
14. Faber LM, van Luxemburg-Heijs SA, Veenhof WF et al. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood 1995; 86: 2821-2828.
15. Krenger W, Ferrara JLM: Graft-versus-host disease and Th1/Th2 paradigm. Immunol Res 1996; 15: 50-73.
16. Byun D-G, Demeure CE, Yang LP et al. In vitro maturation of neonatal human CD8 T lymphocytes into IL-4- and IL-5-producing cells. J Immunol 1994; 153: 4862-4871.
17. + T cells cannot be overcome by CD28 costimulation. Eur J Immunol 1994; 24: 1956-1960.
18. Byrne JA, Butler JL, Reinherz EL, Cooper MD. Virgin and memory T cells have different requirements for activation via the CD2 molecule. Int Immunol 1989; 1: 29-35.
19. Byrne JA, Butler JL, Cooper MD. Differential activation requirements for virgin and memory T cells. J Immunol 1988; 141: 3249-3257.
20. Zola H, Fusco M, Macardle PJ et al. Expression of cytokine receptors by human cord blood lymphocytes: comparison with adult blood lymphocytes. Pediatr Res 1995; 38: 397-403.
21. Zola H, Fusco M, Weedon H et al. Reduced expression of the interleukin-2-receptor gamma chain on cord blood lymphocytes: relationship to functional immaturity of the neonatal immune response. Immunology 1996; 87: 86-91.
22. Saito S, Morii T, Umekage H et al. Expression of the interleukin-2 receptor gamma chain on cord blood mononuclear cells. Blood 1996; 87: 3344-3350.
23. Yang L-P, Byun D-G, Demeure CE et al. Default development of cloned human naive CD4 T cells into interleukin-4 and interleukin-5-producing effector cells. Eur J Immunol 1995; 25: 3517-3520.
24. Early EM, Reen DJ. Antigen-independent responsiveness to interleukin-4 demonstrates differential regulation of newborn human T cells. Eur J Immunol 1996; 26: 2885-2889.